Novel therapies for the treatment of gout
In the past few decades, gout has markedly increased in incidence and prevalence. Gout is a common metabolic disorder characterized by chronic hyperuricemia. The primary cause of this disorder is when urate crystals accumulate in the joint, causing the inflammation and intense pain. Thus, the focus of this study is rapid crystal dissolution with the help of urate-lowering therapy.
This review has highlighted the importance of Urate-lowering therapy and discussed the current treatments including allopurinol, febuxostat, probenecid, benzbromarone and pegloticase. Treatment of pain and inflammation can be achieved with NSAIDs, colchicine, corticosteroids, anti-IL-1 agents and also explored new therapeutic agents for gout which are in Phase III clinical trials.
Major advances have been made in the pharmacotherapy of gout. New developments in strategies and drugs for the management of hyperuricemia and gouty arthritis are benchmarks to improve outcomes in patients with gout. Clinical management guidelines have emphasized on a serum uric acid (SUA) target which is useful in treating gout. Many studies have determined significant dose strategies for old drugs such as allopurinol and colchicine which are safe and effective.
Collectively, novel approaches and drugs have been developed, licensed and hopefully lead to improved management of hyperuricemia and gout. However, quality of care is a greater concern in gout management and clinical outcomes still need to be refined for the future prospects. Therefore, a better understanding of these progresses of the last decade may lead to new diagnostic and therapeutic approaches in gout.